Read our Recent Headlines

May 21st Biotech Update

And today we are green with the rest of the market. There is some biotech news but at this point the sector is trading simply as a slightly higher beta.

May 20 Biotech Update

China and trade seemed to be fading into the background potentially setting this week up for a decline of the highly correlated macro markets but Iran and the Middle East.

May 17th Biotech Update

We remain in a macro driven market even as the ASCO abstracts dropped this week. There were some interesting data that came out of the abstracts but certainly nothing so.

May 15th Biotech Update

Well, yesterday ending up being a good day with the XBI eventually following the individual stocks but this continues to be a highly correlated macro market. The broader market seems.

May 14 Biotech Update

I am not sure who had a more difficult day yesterday. You all for having to watch another market meltdown over China fears (and others) or me who had to.

May 9 Biotech Update

Macro seems to once again dominate the trading with both Iran and China increasing the risk and both North Korea and Venezuela just below the surface. The odds remain that.

May 7th Biotech Update

A good day for the sector despite a relatively bad day for the market. This is a rare occurrence for the sector to outperform (at least recently). One day does.



Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!